| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2021: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the usefulness of combining 2D-SWE and the ultrasound-guided attenuation parameter (UGAP) for assessing the risk of progressive NASH. This prospective study included 202 patients with NAFLD who underwent 2D-SWE, UGAP, and liver biopsy (LB) on the same day. Patients were grouped according to liver stiffness (LS) and the attenuation coefficient (AC): A, low LS/low AC; B, low LS/high AC; C, high LS/low AC; and D, high LS/high AC. The percentages of progressive NASH in Groups A, B, C, and D were 0.0%, 7.7%, 35.7%, and 50.0%, respectively (P<0.001). The prediction model was established as logit (p) = 0.541 × LS (kPa) + 7.79 × AC (dB/cm/MHz) - 8.40, with AUROC, sensitivity, and specificity values of 0.83, 80.9%, and 74.6%, respectively. Combined assessment by 2D-SWE and UGAP is useful for risk stratification of progressive NASH and may be convenient for evaluating the necessity of specialist referral and LB.
|
